Immunotherapy for Extensive-stage Small Cell Lung Cancer:
Research Progress and Future Perspectives.
10.3779/j.issn.1009-3419.2024.102.35
- Author:
Yuling ZHONG
1
;
Jingyi WANG
2
;
Lin WU
2
Author Information
1. Graduate Collaborative Training Base of Hunan Cancer Hospital, University of South China, Hengyang Medical School, Hengyang 421001, China.
2. The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
- Publication Type:English Abstract
- Keywords:
Biomarkers;
Immune checkpoint inhibitors;
Immunotherapy;
Lung neoplasms
- MeSH:
Humans;
Small Cell Lung Carcinoma/pathology*;
Immunotherapy/methods*;
Lung Neoplasms/pathology*;
Immune Checkpoint Inhibitors/therapeutic use*;
Neoplasm Staging;
Animals
- From:
Chinese Journal of Lung Cancer
2024;27(11):855-863
- CountryChina
- Language:Chinese
-
Abstract:
At present, immunotherapy combined with chemotherapy has become the first-line standard of treatment for extensive-stage small cell lung cancer (ES-SCLC). In recent years, immune checkpoint inhibitors (ICIs) have received extensive attention and research in the field of lung cancer. At the same time, there are many challenges and tests in this process, such as the exploration of biomarkers, the exploration of new targets and new models, and the management of special populations. This article reviews the research progress in the field of ES-SCLC immunotherapy, and looks forward to the future development trend and potential direction of this field.
.
